109
Participants
Start Date
February 21, 2018
Primary Completion Date
April 5, 2023
Study Completion Date
April 5, 2023
Isatuximab SAR650984
"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
Cemiplimab REGN2810
"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
Investigational Site Number :3480002, Budapest
Investigational Site Number :0360003, Wollongong
Investigational Site Number :0360002, Richmond
Investigational Site Number :0360001, West Perth
Memorial Sloan-Kettering Cancer Center-Site Number:8400002, New York
Investigational Site Number :3800001, Torino
Investigational Site Number :3000001, Athens
Investigational Site Number :2030001, Prague
Fox Chase Cancer Center-Site Number:8400004, Philadelphia
Investigational Site Number :3800005, Rozzano
Investigational Site Number :3800003, Brescia
Investigational Site Number :7240006, Madrid
Investigational Site Number :2500002, Nantes
Investigational Site Number :7240005, Valencia
Investigational Site Number :2500004, Lille
Investigational Site Number :2030002, Brno
Investigational Site Number :2500003, Pierre-Bénite
Investigational Site Number :2030003, Ostrava - Poruba
University of Colorado-Site Number:8400001, Denver
Investigational Site Number :2500001, Villejuif
University of Kansas Medical Center-Site Number:8400003, Kansas City
Investigational Site Number :0760003, Goiânia
Investigational Site Number :0760001, Porto Alegre
Investigational Site Number :0760004, São Paulo
Investigational Site Number :1240001, Montreal
Investigational Site Number :1240005, Montreal
Investigational Site Number :1240003, Sherbrooke
Investigational Site Number :7240003, Barcelona
Investigational Site Number :7240004, Badalona
Investigational Site Number :7240002, Barcelona
Lead Sponsor
Sanofi
INDUSTRY